Biomarker-based Trial of NPC-1 for Alzheimer's Pathology

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Massachusetts General Hospital
Study ID
NCT07236190
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
55 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • natural product combination-1 (NPC1) — COMBINATION_PRODUCT
    parthenolide plus ipriflavone

Study Details

This early phase, open label, single arm clinical trial will determine the intraindividual safety, tolerability and effects of NPC1 (parthenolide and ipriflavone) on blood-based biomarkers of Alzheimer's disease (AD) pathology among adults with subjective cognitive decline, mild cognitive impairment, or Alzheimer's disease and objective indicators of seeding AD pathology

Key Dates

Start date
Apr 1, 2026
Status verified
Jun 2026
Primary completion
Jun 30, 2027
Completion
Jun 30, 2027

Study Design

Enrollment
40 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • No Intervention: Lead-in observational period
    Serial blood-based biomarker collection
  • Active Comparator: Active interventional period
    Serial post treatment blood-based biomarkers

Primary Outcome Measure

plasma p-tau217 [ Time Frame: 6 months ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Massachusetts General HospitalBostonMassachusetts02129
Gene L. Bowman, ND, MPH
[email protected]
857-282-5197

Find similar trials in Boston, MA

By condition
Alzheimer's disease
By specialty
NeurologyDementia careBrain disordersGeriatrics
By research site
Massachusetts General Hospital· Boston, MA

Related Studies